search
Back to results

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Primary Purpose

Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Neoantigen mRNA Personalised Cancer SW1115C3
Sponsored by
Stemirna Therapeutics
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumor

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Are 18 to 80 years old (including boundary values), without limitation of sex at time of consent.
  • Based on the RECIST 1.1 criteria for disease progression, (a maximum increase in tumour diameter of 20%) for participants undergoing prescreening who are receiving standard treatment, these participants may reach the defined disease progression criteria at the time of tumour vaccine administration.

Exclusion Criteria:

  • Have used a live attenuated vaccine within 4 weeks before the first use of SW1115C3 with the following exceptions:
  • Adverse reactions induced by previous anti-tumour treatments have not yet recovered to Grade ≤ 1 (except for toxicity evaluated to have no risk of safety by the PI [or designee], such as hair loss, Grade 2 peripheral neurotoxicity and hypothyroidism stabilised by hormone-replacement therapy) based on NCI CTCAE version 5.0.

Sites / Locations

  • Pindara Private HospitalRecruiting
  • Peninsula & South Eastern Haematology and Oncology GroupRecruiting
  • One Clinical ResearchRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Neoantigen mRNA Personalised Cancer

Arm Description

This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.

Outcomes

Primary Outcome Measures

,Dose-limiting toxicity incidence (participants who experience DLT)

Secondary Outcome Measures

Objective response rate(ORR) assessment per RECIST Version 1.1

Full Information

First Posted
January 5, 2022
Last Updated
October 12, 2022
Sponsor
Stemirna Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT05198752
Brief Title
A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors
Official Title
A Phase 1 Clinical Study to Evaluate the Tolerability, Safety,Immunogenicity and Efficacy of the Neoantigen mRNA Personalised Cancer Vaccine SW1115C3 in Patients With Advanced Malignant Solid Tumours
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 18, 2022 (Actual)
Primary Completion Date
December 22, 2023 (Anticipated)
Study Completion Date
June 12, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Stemirna Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase 1 open label study to evaluate the tolerability, safety, immunogenicity, and efficacy of SW1115C3, a neoantigen mRNA personalised cancer vaccine, in patients with advanced malignant solid tumours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
30 participants in Cohort (C)1:50 mcg of SW1115C3 ; C2: 100 mcg of SW1115C3; C3: 150 mcg of SW1115C3.
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Neoantigen mRNA Personalised Cancer
Arm Type
Experimental
Arm Description
This study is a 3+3 dose escalation design. Participants will receive a total of 6 cycles of SW1115C3 every 21 days.
Intervention Type
Drug
Intervention Name(s)
Neoantigen mRNA Personalised Cancer SW1115C3
Intervention Description
Subcutaneous Injection
Primary Outcome Measure Information:
Title
,Dose-limiting toxicity incidence (participants who experience DLT)
Time Frame
21 day
Secondary Outcome Measure Information:
Title
Objective response rate(ORR) assessment per RECIST Version 1.1
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Are 18 to 80 years old (including boundary values), without limitation of sex at time of consent. Based on the RECIST 1.1 criteria for disease progression, (a maximum increase in tumour diameter of 20%) for participants undergoing prescreening who are receiving standard treatment, these participants may reach the defined disease progression criteria at the time of tumour vaccine administration. Exclusion Criteria: Have used a live attenuated vaccine within 4 weeks before the first use of SW1115C3 with the following exceptions: Adverse reactions induced by previous anti-tumour treatments have not yet recovered to Grade ≤ 1 (except for toxicity evaluated to have no risk of safety by the PI [or designee], such as hair loss, Grade 2 peripheral neurotoxicity and hypothyroidism stabilised by hormone-replacement therapy) based on NCI CTCAE version 5.0.
Facility Information:
Facility Name
Pindara Private Hospital
City
Benowa
State/Province
Queensland
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrea Tazbirkova
Phone
0756576400
Email
dratazbirkova@iconcancercare.com.au
First Name & Middle Initial & Last Name & Degree
Andrea Tazbirkova
Facility Name
Peninsula & South Eastern Haematology and Oncology Group
City
Frankston
State/Province
Victoria
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vinod Ganju
Phone
0397815244
Email
vg@paso.com.au
First Name & Middle Initial & Last Name & Degree
Vinod Ganju
Facility Name
One Clinical Research
City
Nedlands
State/Province
Western Australia
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mihitha Ariyapperuma
Phone
0862799466
Email
mihitha.ariyapperuma@oneclinicalresearch.com.au
First Name & Middle Initial & Last Name & Degree
Mihitha Ariyapperuma

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

We'll reach out to this number within 24 hrs